zoledronic acid vs pamidronate
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Osteopenia
Conditions
Osteopenia, Complications of Heart-lung Transplant, Other Complications of Lung Transplant
Trial Timeline
Oct 1, 2002 → Dec 1, 2005
NCT ID
NCT00164008About zoledronic acid vs pamidronate
zoledronic acid vs pamidronate is a approved stage product being developed by Novartis for Osteopenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00164008. Target conditions include Osteopenia, Complications of Heart-lung Transplant, Other Complications of Lung Transplant.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00164008 | Approved | Completed |
Competing Products
18 competing products in Osteopenia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Teriparatide + Zoledronic Acid | Eli Lilly | Approved | 85 |
| alendronate sodium | Merck | Approved | 85 |
| zoledronic acid | Novartis | Phase 3 | 77 |
| Zoledronic Acid + Placebo | Novartis | Phase 3 | 77 |
| BPS804 20mg/Kg + Placebo to 20mg/Kg BPS804 | Novartis | Phase 2 | 52 |
| Placebo + ibandronate [Bonviva/Boniva] | Roche | Approved | 85 |
| ibandronate [Bonviva/Boniva] + Placebo | Roche | Phase 3 | 77 |
| Romosozumab + Placebo | Amgen | Phase 1 | 32 |
| Placebo + AMG 167 | Amgen | Phase 1 | 32 |
| AMG 167 + Placebo | Amgen | Phase 1 | 32 |
| Romosozumab + Placebo | Amgen | Phase 1 | 32 |
| Denosumab | Amgen | Phase 3 | 76 |
| Romosozumab + Placebo | Amgen | Phase 1 | 32 |
| Dasatinib 100 Mg Oral Tablet | Novo Nordisk | Phase 2 | 51 |
| RN564 | Pfizer | Phase 1 | 32 |
| risedronate + alendronate | Sanofi | Phase 1 | 32 |
| Menostar (Estradiol, BAY86-5435) + Raloxifene | Bayer | Phase 3 | 74 |
| tibolone + raloxifen | Organon | Approved | 80 |